Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Data_Sheet_5_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

“…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Representative examples of LBNP and LBPP/hypoxia experiment. by Marcus Thudium (6441863)

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”

The average speed of the model (step length/step duration), <i>v</i>, vs. the phase of a perturbation pulse, <i>φ</i> for a pulse of constant amplitude and duration. by Jooeun Ahn (299192)

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Pharmacologically induced torpor by 5′-AMP does not decrease platelet count despite decreased body temperature. by Edwin L. de Vrij (550179)

“…<p>A) Pharmacologically induced torpor by 5′-AMP in mice does not decrease platelet count during torpor and shows an increase upon arousal. …”

Fig 5 - by Jacob C. Jentzer (4746999)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Metabolic and molecular effects of high-fat diet (HFD). by Ping-yu Cai (12389929)

Fig 9 - by Jianbo Jia (717814)

Subjects:

Experimental procedure. by Nakako Okamoto (18501452)

HS increases and CCL20 antibody decreases Th17-related cytokines in IgAN mice. by Ting Meng (613774)

Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)